

Resource Summary Report

Generated by T1D on Aug 3, 2026

Ximbio

RRID:SCR_015867

Type: Tool

Proper Citation

Ximbio (RRID:SCR_015867)

Resource Information

URL: <https://ximbio.com/>

Proper Citation: Ximbio (RRID:SCR_015867)

Description: Biobank for reagents such as antibodies, mice, and cell lines. Ximbio aims to maximise scientists' commercial opportunities and encourage the sharing of tools and information among the research community.

Synonyms: Ximbio Biobank

Resource Type: material storage repository, data or information resource, biobank, database, service resource, storage service resource

Keywords: biobank, reagent, antibody, mouse, cell line, collaborative tool, research community

Availability: Available to the scientific community, The scientific community can contribute to this resource, Non-profit

Resource Name: Ximbio

Resource ID: SCR_015867

Record Creation Time: 20220129T080327+0000

Record Last Update: 20260803T040705+0000

Ratings and Alerts

No rating or validation information has been found for Ximbio.

No alerts have been found for Ximbio.

Data and Source Information

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Perrichet A, et al. (2025) Cancer cell-derived IL-1 β reverses chemo-immunotherapy resistance in non-small cell lung cancer. *Nature communications*, 16(1), 10244.

Ye J, et al. (2025) Stromal modifying CHST15 siRNA enhances antitumor effect synergistically with anti-PD-1 immune checkpoint antibody in murine pancreatic cancer. *Scientific reports*, 15(1), 20365.

Jeon YH, et al. (2024) Observation of neutrophil extracellular traps in the development of diabetic nephropathy using diabetic murine models. *Laboratory animal research*, 40(1), 38.

Huang Z, et al. (2024) Exploiting sweet relief for preeclampsia by targeting autophagy-lysosomal machinery and proteinopathy. *Experimental & molecular medicine*, 56(5), 1206.

Spear S, et al. (2024) PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma. *Cancer research*, 84(22), 3772.

Wang C, et al. (2024) Utilizing human cerebral organoids to model breast cancer brain metastasis in culture. *Breast cancer research : BCR*, 26(1), 108.

Borrelli C, et al. (2024) In vivo interaction screening reveals liver-derived constraints to metastasis. *Nature*, 632(8024), 411.

Tintelnot J, et al. (2023) Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. *Nature*, 615(7950), 168.

Woeste MR, et al. (2023) Irreversible electroporation augments β -glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma. *Journal for immunotherapy of cancer*, 11(4).

Pivetta TP, et al. (2023) Phototoxic Potential of Different DNA Intercalators for Skin Cancer Therapy: In Vitro Screening. *International journal of molecular sciences*, 24(6).

McAloney CA, et al. (2023) Host-derived growth factors drive ERK phosphorylation and MCL1 expression to promote osteosarcoma cell survival during metastatic lung colonization. *Cellular oncology (Dordrecht)*.

Geller AE, et al. (2022) The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. *Nature communications*, 13(1), 759.

Falcone M, et al. (2022) Sensitisation of cancer cells to radiotherapy by serine and glycine starvation. *British journal of cancer*, 127(10), 1773.

Song DA, et al. (2022) A New Monoclonal Antibody Enables BAR Analysis of Subcellular Importin β 1 Interactomes. *Molecular & cellular proteomics : MCP*, 21(11), 100418.

Newman AC, et al. (2021) Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells. *Molecular cell*, 81(11), 2290.

Shorrocks AK, et al. (2021) The Bloom syndrome complex senses RPA-coated single-stranded DNA to restart stalled replication forks. *Nature communications*, 12(1), 585.

Said Z, et al. (2021) Corticosteroid delivery using oral mucosa equivalents for the treatment of inflammatory mucosal diseases. *European journal of oral sciences*, 129(2), e12761.

Adhikari H, et al. (2021) Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. *Nature communications*, 12(1), 5248.

Phan T, et al. (2021) Inhibition of de novo pyrimidine synthesis augments Gemcitabine induced growth inhibition in an immunocompetent model of pancreatic cancer. *International journal of biological sciences*, 17(9), 2240.

Rossi Sebastiano M, et al. (2020) ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. *Science advances*, 6(44).